medigraphic.com
ISSN 2221-2434 (Digital)

2014, Número 2

<< Anterior Siguiente >>

Finlay 2014; 4 (2)


La prevención y regresión de la ateroesclerosis: tratamientos emergentes

Rodríguez RA, Rodríguez JG

Idioma: Español
Referencias bibliográficas: 68
Paginas: 117-129
Archivo PDF: 156.88 Kb.


RESUMEN

Las enfermedades vasculares oclusivas, como el síndrome coronario agudo, el accidente cerebrovascular, y la enfermedad arterial periférica, representan un serio problema de salud a nivel mundial. En las últimas décadas se han realizados importantes avances en el diagnóstico y tratamiento de la ateroesclerosis. El ultrasonido intravascular aporta información detallada de la anatomía de la placa y ha sido utilizado en varios estudios para evaluar los resultados. La presencia de aterosclerosis desestabiliza el mecanismo protector normal provisto por el endotelio y este mecanismo ha estado implicado en la fisiopatología de la enfermedad coronaria aguda y el accidente cerebrovascular. Los mayores esfuerzos están dirigidos a la prevención, sobre todo en edades tempranas. El presente trabajo es una revisión de 68 referencias bibliográficas actualizadas con el objetivo de exponer las opciones actuales disponibles en la prevención y reversión del proceso ateroesclerótico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation. 2012 ; 125 (22): 188-97.

  2. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.. Circulation. 2011 ; 123 (8): 933-44.

  3. Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology. 2007 ; 58 (5): 513-22.

  4. Fleming RM. The effect of high-moderate-and low-fat diets on weight loss and cardiovascular disease risk factors. Prev Cardiol. 2002 ; 5 (3): 110-8.

  5. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007 ; 115 (10): 1285-95.

  6. Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol. 2012 ; 10 (1): 4-18.

  7. Shah PK. Molecular mechanisms of plaque instability. Curr Opin Lipidol. 2007 ; 18 (5): 492-9.

  8. Calabresi L, Simonelli S, Gomaraschi M, Franceschini G. Genetic lecithin: cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis. 2012 ; 222 (2): 299-306.

  9. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol. 2013 ; 62 (13): 1131-43.

  10. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006 ; 47 Suppl 8: SC7-C12.

  11. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011 ; 364 (3): 226-35.

  12. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999 ; 340 (1): 14-22.

  13. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K, el al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003 ; 107 (11): 1562-6.

  14. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. American Heart Association 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010 ; 56 (25): e50-103.

  15. Gidding SS, Lichtenstein AH, Faith MS, Karpyn A, Mennella JA, Popkin B, et al. Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation. 2009 ; 119 (8): 1161-75.

  16. Zeb I, Budoff MJ. MESA: The NIH-sponsored study that validates atherosclerosis imaging for primary prevention. Curr Atheroscler Rep. 2011 ; 13 (5): 353-8.

  17. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, et al. From vulnerable plaque to vulnerable patient – Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol. 2006 ; 98 (2A): 2H-15H.

  18. Aguilar AL, Gallardo C, Garrido S, Calvo E, Zamorano JL. Carotid intima-media thickness as a screening tool in cardiovascular primary prevention. Eur J Clin Invest. 2011 ; 41 (5): 521-6.

  19. Hecht HS. The role of atherosclerosis imaging in redefining normal and abnormal cholesterol values, and risk reduction in primary prevention statin trials. Curr Atheroscler Rep. 2011 ; 13 (5): 422-30.

  20. Lenfant F, Trémolliéres F, Gourdy P, Arnal JF. Timing of the vascular actions of estrogens in experimental and human studies: why protective early, and not when delayed?. Maturitas. 2011 ; 68 (2): 165-73.

  21. Deniset JF, Pierce GN. Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis. Fundam Clin Pharmacol. 2010 ; 24 (5): 607-17.

  22. Pashkow FJ. Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention?. Int J Inflam. 2011 (1): 514-623.

  23. Reis JP, Loria CM, Steffen LM, Zhou X, van Horn L, Siscovick DS, et al. Coffee, decaffeinated coffee, caffeine, and tea consumption in young adulthood and atherosclerosis later in life: the CARDIA study. Arterioscler Thromb Vasc Biol. 2010 ; 30 (10): 2059-66.

  24. Muntendam P, McCall C, Sanz J, Falk E, Fuster V; High-Risk Plaque Initiative. The Biolmage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease – study design and objectives. Am Heart J. 2010 ; 160 (1): 49-57.

  25. Dauchet L, Amouyel P, Dallongeville J. Fruits, vegetables and coronary heart disease. Nat Rev Cardiol. 2009 ; 6 (9): 599-608.

  26. Jablecka A, Bogdański P, Balcer N, Cieślewicz A, Skołuda A, Musialik K. The effect of oral L-arginine supplementation on fasting glucose, HbA1c, nitric oxide and total antioxidant status in diabetic patients with atherosclerotic peripheral arterial disease of lower extremities. Eur Rev Med Pharmacol Sci. 2012 ; 16 (3): 342-50.

  27. Szostak J, Laurant P. The forgotten face of regular physical exercise: a “natural” anti-atherogenic activity. Clin Sci (Lond). 2011 ; 121 (3): 91-106.

  28. Ahmed HM, Blaha MJ, Nasir K, Rivera JJ, Blumenthal RS. Effects of physical activity on cardiovascular disease. Am J Cardiol. 2012 ; 109 (2): 288-95.

  29. Ford MA, Allison TG, Lerman A. New approaches to the concept of primary prevention of atherosclerosis. Curr Treat Options Cardiovasc Med. 2008 ; 10 (1): 73-82.

  30. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011 ; 124 (22): 2458-73.

  31. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. World Heart Federation and the Preventive Cardiovascular Nurses Association AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol. 2011 ; 58 (23): 2432-46.

  32. Lichtman JH, Bigger JT Jr, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lespérance F, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008 ; 118 (17): 1768-75.

  33. Leon AS, Franklin BA, Costa F, Balady GJ, Berra KA, Stewart KJ, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2005 ; 111 (3): 369-76.

  34. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/ SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation. 2011 ; 124 (4): 489-532.

  35. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 ; 361 (11): 1045-57.

  36. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 ; 357 (20): 2001-15.

  37. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation. 2010 ; 121 (10): 1176-87.

  38. García HM, Garg S, Brugaletta S, Morocutti G, Ratner RE, Kolatkar NS, et al. Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients with Cardiovascular History). Int J Cardiovasc Imaging. 2012 ; 28 (3): 455-65.

  39. Francis AA, Pierce GN. An integrated approach for the mechanisms responsible for atherosclerotic plaque regression. Exp Clin Cardiol. 2011 ; 16 (3): 77-86.

  40. Bedi U, Singh M, Singh P, Molnar J, Khosla S, Arora R. Effects of statins on progression of coronary artery disease as measured by intravascular ultrasound. J Clin Hypertens (Greenwich). 2011 ; 13 (7): 492-6.

  41. Han SH, Chung WJ, Kang WC, Lee K, Park YM, Shin MS, et al. Rosuvastatin combined with ramipril significantly reduced atheroma volume by anti-inflammatory mechanism: comparative analysis with rosuvastatin alone by intravascular ultrasound. Int J Cardiol. 2012 ; 158 (2): 217-24.

  42. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J. 2009 ; 73 (11): 2110-7.

  43. Hibi K, Kimura T, Kimura K, Morimoto T, Hiro T, Miyauchi K, et al. Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial. Atherosclerosis. 2011 ; 219 (2): 743-9.

  44. Arai H, Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, et al. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome – sub-analysis of JAPAN-ACS study. J Atheroscler Thromb. 2010 ; 17 (10): 1096-107.

  45. Tani S, Nagao K, Anazawa T, Kawamata H, Furuya S, Takahashi H, et al. Relation of change in apolipoprotein B/apolipoprotein A–I ratio to coronary plaque regression after Pravastatin treatment in patients with coronary artery disease. Am J Cardiol. 2010 ; 105 (2): 144-8.

  46. Migrino RQ, Bowers M, Harmann L, Prost R, LaDisa JF. Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness. J Cardiovasc Magn Reson. 2011 ; 13 (1): 37.

  47. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011 ; 365 (22): 2078-87.

  48. Yang HB, Zhao XY, Zhang JY, Du YY, Wang XF. Pioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose tolerance. Diabet Med. 2012 ; 29 (3): 359-65.

  49. Godin B, Sakamoto JH, Serda RE, Grattoni A, Bouamrani A, Ferrari M. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci. 2013 ; 31 (5): 199-205.

  50. Lobatto ME, Fuster V, Fayad ZA, Mulder WJ. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov. 2011 ; 10 (11): 835-52.

  51. O´Neil CP, van der Vlies AJ, Velluto D, Wandrey C, Demurtas D, Dubochet J, et al.. Extracellular matrix binding mixed micelles for drug delivery applications. J Control Release. 2009 ; 137 (2): 146-51.

  52. Chan JM, Zhang L, Tong R, Ghosh D, Gao W, Liao G, et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci USA. 2010 ; 107 (5): 2213-8.

  53. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977 ; 62 (5): 707-14.

  54. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A–I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 ; 104 (10): 1108-13.

  55. Forrester JS, Shah PK. Emerging strategies for increasing high-density lipoprotein. Am J Cardiol. 2006 ; 98 (11): 1542-9.

  56. Van der Steeg WA, Kuivenhoven JA, Klerkx AH, Boekholdt SM, Hovingh GK, Kastelein JJ. Role of CETP inhibitors in the treatment of dyslipidemia. Curr Opin Lipidol. 2004 ; 15 (6): 631-6.

  57. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011 ; 378 (9802): 1547-59.

  58. Gutstein DE, Krishna R, Johns D, Surks HK, Dansky HM, Shah S, et al. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther. 2012 ; 91 (1): 109-22.

  59. Cannon CP, Dansky HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, et al. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009 ; 158 (4): 513-9.

  60. Chen F, Maccubbin D, Yan L, Sirah W, Chen E, Sisk CM, et al. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int J Cardiol. 2013 ; 167 (1): 225-31.

  61. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004 ; 110 (23): 3512-7.

  62. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010 ; 55 (24): 2721-6.

  63. University of Washington. Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy) [Internet]. Bethseda: US National Library of Medicine; 2010. [ cited 12 Jun 2012 ] Available from: http://www.clinicaltrials.gov/ct2/show/NCT011783 20.

  64. University of Washington. Plaque Inflammation and Dysfunctional HDL Cholesterol in Participants Receiving Niacin and Statins in the AIM-HIGH Study (The HDL Proteomics Study) [Internet]. Bethseda: US National Library of Medicine; 2009. [ cited 23 Feb 2012 ] Available from: http://www.clinicaltrials.gov/ct2/show/NCT008801

  65. Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005 ; 27 (8): 1181-95.

  66. Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr Med Res Opin. 2006 ; 22 (12): 2575-90.

  67. Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M, et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care. 2004 ; 27 (6): 1324-9.

  68. Tardif JC, Grégoire J, L´Allier PL, Ibrahim R, Lespérance J, Heinonen TM, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007 ; 297 (15): 1675-82.




2020     |     www.medigraphic.com